Semnur Pharmaceuticals to go public in SPAC deal of up to $2 billion with Denali Capital
02/07/2024 22:48
July 2 (Reuters) - Drug developer Semnur Pharmaceuticals
said on Tuesday it has signed a letter of intent to go public
through a merger with special purpose acquisition company Denali
Capital Acquisition Corp DECA.O in a pre-transaction equity
deal valued at up to $2 billion.
Semnur is a unit of Scilex Holding SCLX.O .
(Reporting by Mariam Sunny in Bengaluru; Editing by Krishna
Chandra Eluri)
((Mariam.ESunny@thomsonreuters.com;))
Recent news on Scilex Holding
See all newsEnters Promissory Note With Vivasor For Revolving Credit Up To $20 Million, On Aug 8
Brief: Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens To List On Biconomy Exchange As Early As June 23, 2026
Brief: O+C Private Credit Wade Defendants Dispute Complaint And Statement By Scilex Holding Company
Company Enters Binding Term Sheet With Datavault Ai - SEC Filing
Company May Offer Up To $500 Million In Securities - SEC Filing